In 2030, the global monoclonal antibody market will be nearly 500 billion US dollars, with a CAGR of 11.30%

The global monoclonal antibody (mAbs) market is expected to reach USD 494.53 billion by 2030, growing at a compound annual growth rate (CAGR) of 11.30% over the forecast period. Rising R&D activities to develop novel therapeutic monoclonal antibodies and government supportive initiatives for the production of biologics will propel the market growth.

Research and Market, a well-known industry intelligence agency, recently reported in its “2022-2030 Monoclonal Antibody Market Size, Share and Trend Analysis Report (by source type (chimeric, mouse, humanized, human-derived)” ), production type (in vivo, in vitro), application, end-use, region and segment forecasts)” report made the above forecasts.

The growing demand for personalized medicine may have a positive impact on the development of therapeutic mAb-targeted therapies tailored to individual needs. In addition, the therapeutic application of monoclonal antibodies offers many advantages compared to traditional treatment options, such as fewer adverse reactions, strong treatment specificity, and high capacity for large-scale production, and can significantly drive market growth.

In addition, several government entities are promoting clinical research activities and expanding the use of monoclonal antibody therapeutics. For example, in June 2022, the National Institutes of Health launched a clinical trial evaluating dupilumab (Dupixent, Sanofi) to reduce asthma attacks and improve lung performance in children Function.

Similarly, in March 2021, the US Department of Health and Human Services invested $150 million to increase patients’ access to Covid-19 monoclonal antibody therapy. These moves are expected to increase the use of monoclonal antibodies and enhance growth prospects.

In addition, technological advances in genetic engineering, DNA cloning, and various peptide and protein display technologies have facilitated the production and optimization of recombinant monoclonal antibodies. The demand for such recombinant antibodies is driven by growing commercial prospects and quality requirements that may not be met by hybridoma technology. Hence, the market is expected to grow significantly as the commercial viability of the recombinant technology improves.

The COVID-19 pandemic has created some market expansion opportunities by driving the development of several monoclonal antibodies against the SARS-CoV-2 virus.

Several monoclonal antibodies, including Eli Lilly’s bebtelovimab and GlaxoSmithKline’s sotrovimab, have received emergency use from the US FDA as monoclonal antibodies are a promising alternative for disease mitigation due to their safety and efficacy authorized. Such authorizations are likely to broaden the growth prospects of monoclonal antibody applications and drive market growth.

The Monoclonal Antibody Market report has the following highlights:

In terms of source type, humanized monoclonal antibody fragments will account for the largest share of 54.07% in 2021 due to the low immunogenicity of antibodies and their increasing applications in cancer treatment.

Owing to the low contamination level and advanced biomanufacturing capability offered by this technology, in vitro production type holds a dominant share of 78.45% in 2021.

In 2021, the oncology segment will dominate the market due to the increasing number of approvals of monoclonal antibody cancer therapies and the increasing scientific and patient awareness of such therapies.

Hospitals will account for the largest share of the end-use segment in 2021, owing to the widespread use of monoclonal antibodies in hospital-based cancer treatment and increasing healthcare spending favoring the adoption of such therapies.

In 2021, North America will account for 46.2% of the market value due to the availability of advanced healthcare infrastructure, high growth in cancer incidence, and the local presence of key companies such as Pfizer, Amgen, and Merck.

Asia Pacific is expected to witness the highest growth rate over the forecast period owing to the large number of cancer treatment patients in the region and the expanding clinical research prospects of monoclonal antibodies.

This article is reproduced from the frontier of new drugs